Entities / Company
Rocket.
Company
- Reports this week
- 0
- Active events
- 0
- Connections
- 32
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Earlier this month
One to three months ago
-
Rocket, a pharmaceutical company, is trading on the Nasdaq stock exchange. A legal filing disclosed a stock sale involving the company's COO, Christopher James Stevens.Some support1 report
-
Redfin is powered by Rocket, and Yingqi Xu is a Senior Economist at Redfin.Some support8 reports
-
The FDA placed a clinical hold on the Phase 2 study of Rocket Pharmaceuticals Inc. on August 11, 2025.Some support2 reports
-
Stock price of Rocket reported by Benzinga data, influenced by market trends observed by Redfin.Some support1 report
Gone quiet
No new reports in 90+ days-
Rocket Pharmaceuticals trades on the Nasdaq stock exchange.Some support5 reports
-
FDA granted priority review for a gene therapy, while the company Rocket was listed on the Nasdaq stock exchange.Some support1 report
-
Anticipated FDA decision on RP-A501 approval, Jefferies raised price target on RCKT stock, and potential benefits from Trump-era tariffs.Well supported3 reports
-
FDA approval of KRESLADI may grant Priority Review Voucher.Some support1 report
-
Corporate filings confirm the incorporation status of several entities related to Rocket, including Eclipse Sub and Rocket GP, in Michigan.Some support1 report
-
FDA granted RMAT designation to Rocket's therapy, and Kinnari Patel was identified as President and Head of R&D.Some support2 reports
-
The FDA accepted a resubmission for T cell immunotherapy tab-cel while simultaneously rejecting approval for Rocket's gene therapy Kresladi.Some support1 report
-
The FDA lifted a clinical trial hold on August 20, 2025, allowing trials to resume for companies including Sangamo Therapeutics and Bluebird.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around Rocket this week
News at the entities that move Rocket most-
FDA StructuralThe FDA has listed recalled products, involving the company Colgate.Moves Rocket
-
Nasdaq StructuralKelly Services, a staffing company, serves the Americas and trades on the Nasdaq stock exchange.Moves Rocket
-
SEC StructuralCrane filed reports with the SEC and James Tullis was identified as a director of the company.Moves Rocket
-
Redfin StructuralBLS data informs inflation projections and Redfin reports median home sales price in Los Angeles.Moves Rocket
-
Jim Cramer Mentioned togetherJim Cramer warned about Whirlpool's dividend suspension on October 24, 2026.Moves Rocket
-
Detroit Shared contextSupport from Detroit and Atlanta is influencing the Michigan Senate contest and Georgia governor's race, while Trump's ratings shift affects midterms.Moves Rocket
Connections
The 11 strongest of 32, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
FDA Structural
The FDA formally regulates Rocket's drug development, issuing clearances, designations, and clinical holds.
-
Gaurav Shah Structural
Gaurav Shah serves as the Chief Executive Officer of Rocket Pharmaceuticals.
-
Nasdaq Structural
Rocket is formally listed and trades on the Nasdaq stock exchange.
-
Redfin Structural
Redfin relies on Rocket's core technology for its operations, while market trends influence Rocket.
-
SEC Structural
Rocket is required to file registration statements with the SEC as part of its regulatory compliance.
-
ValueAct Capital Transactional
ValueAct Capital increased its financial stake in Rocket.
-
Jim Cramer Mentioned together
Jim Cramer, a financial commentator, discussed Rocket's stock performance on air.
-
Rio de Janeiro Shared context
The company operates within the geographical and operational context of the city of Rio de Janeiro.
Show all 11 connections
-
Florence Pugh Mentioned together
Rocket is portrayed as a character in a film featuring Florence Pugh.
-
Detroit Shared context
Rocket is identified as a fintech platform company based in Detroit.
-
Benzinga Mentioned together
Benzinga reports on Rocket's stock price data.
History
Events by the month they beganSeptember 2026
1 eventAugust 2026
2 eventsJuly 2026
1 eventShow 1 earlier month
June 2026
10 events- Asad Khan is a Senior Economist at Redfin, and Redfin is powered by Rocket.
- The FDA placed a clinical hold on the Phase 2 study of Rocket Pharmaceuticals Inc. on August 11, 2025.
- Rocket Pharmaceuticals trades on the Nasdaq stock exchange.
- FDA granted priority review for a gene therapy, while the company Rocket was listed on the Nasdaq stock exchange.
- Anticipated FDA decision on RP-A501 approval, Jefferies raised price target on RCKT stock, and potential benefits from Trump-era tariffs.
- FDA approval of KRESLADI may grant Priority Review Voucher.
- Corporate filings confirm the incorporation status of several entities related to Rocket, including Eclipse Sub and Rocket GP, in Michigan.
- FDA granted RMAT designation to Rocket's therapy, and Kinnari Patel was identified as President and Head of R&D.
- The FDA accepted a resubmission for T cell immunotherapy tab-cel while simultaneously rejecting approval for Rocket's gene therapy Kresladi.
- The FDA lifted a clinical trial hold on August 20, 2025, allowing trials to resume for companies including Sangamo Therapeutics and Bluebird.